

SHORT COMMUNICATION



Cancer biomarkers: Key to personalized treatment and improved case outcomes

Amisha Biswal¹ and Priyanka Prusty¹

¹Department of Biotechnology, Utkal University, Bhubaneswar, Odisha, India

ABSTRACT

Cancer continues to be one of the leading causes of morbidity and mortality worldwide. The complications and diversity of the complaint bear the development of more effective and targeted treatment strategies. Cancer biomarkers, which include inheritable, proteomic, and epigenetic pointers, have surfaced as vital tools for early opinion, prognostic, and monitoring of remedial efficacy. individualized treatment, which knitter's curatives grounded on individual molecular biographies, has gained significant attention in recent times. This composition discusses the significance of cancer biomarkers in the environment of individualized drug, their part in enhancing case issues, and the challenges and unborn directions of biomarker- grounded diagnostics and curatives.

KEYWORDS

Cancer biomarkers;
Molecular profiling; Cancer
diagnosis; Liquid biopsy;
Therapeutic
monitoring

ARTICLE HISTORY

Received 25 October 2024;
Revised 25 November 2024;
Accepted 06 December
2024

Introduction

Cancer is a multifaceted complaint, characterized by unbridled cell growth and spread to other corridors of the body. Due to its complexity, the operation of cancer has traditionally been challenging. Historically, treatment strategies, including chemotherapy, radiation, and surgery, have followed a one- size-fits- all approach. Still, this system doesn't always affect optimal issues, as cancer can vary significantly across individualities in terms of inheritable makeup, molecular characteristics, and excrescence medium [1].

In recent times, the field of cancer exploration has witnessed significant progress in understanding the molecular and inheritable underpinnings of excrescences, giving rise to the conception of substantiated or perfection drug. At the heart of individualized cancer treatment is the identification and operation of cancer biomarkers. These biomarkers, which can be deduced from excrescence cells, blood, urine, or other fleshly fluids, serve as pointers of cancer presence, progression, and response to treatment [1,2]. By relating specific biomarkers, clinicians can prognosticate which curatives will be most effective for a particular case, thereby perfecting survival rates and minimizing side goods.

This composition explores the critical part of cancer biomarkers in individualized treatment, how they contribute to bettered case issues, and the challenges faced in biomarker discovery and clinical perpetration [2,3].

Cancer Biomarkers and Their Types

Cancer biomarkers are motes, or inheritable differences present in excrescence cells or the body's response to excrescence. They can be used for early opinion, staging, prognosticating treatment response, and covering rush. There are several types of cancer biomarkers, distributed grounded on their function and origin [4].

Inheritable Biomarkers These are differences in the DNA sequence that are associated with cancer. Mutations in specific genes can lead to cancer development. inheritable biomarkers are frequently used to identify cases who may profit from targeted

curatives. For illustration, mutations in the epidermal growth factor receptor (EGFR) gene are common in non-small cell lung cancer (NSCLC) and can guide the use of EGFR impediments [4,5].

Proteomic Biomarkers Proteomic biomarkers involve changes in protein expression or revision that can indicate the presence of cancer. They can be linked through technologies similar as mass spectrometry and enzyme-linked immunosorbent assay (ELISA). exemplifications include the prostate-specific antigen (PSA) for prostate cancer and HER2 for bone cancer [6].

Epigenetic Biomarkers These biomarkers involve variations to DNA that do not change the beginning inheritable sequence but can affect gene expression [6,7]. Methylation patterns are one of the most studied forms of epigenetic variations and can be used to diagnose and prognose cancers, like in the case of colorectal cancer.

MicroRNA Biomarkers MicroRNAs are small RNA motes that regulate gene expression. Aberrant microRNA expression has been associated with colorful cancers, and their discovery in blood or towel samples can give perceptivity into excrescence geste and remedial responses [8,9].

This table 1 indicates just a few examples of how cancer biomarkers can be employed to guide opinion and treatment, emphasizing their significance in individualized cancer care [10].

Table 1. Examples of Cancer biomarkers and their Applications

Biomarker	Cancer Type	Clinical Application
EGFR Mutation	NSCLC	Predicts response to EGFR inhibitors like gefitinib and erlotinib
HER2 Amplification	Breast cancer	Guides use of HER2-targeted therapies such as trastuzumab
BRAF Mutation	Melanoma	Indicates benefit from BRAF inhibitors like vemurafenib
PSA	Prostate cancer	Used for screening, diagnosis, and monitoring treatment response
CA-125	Ovarian cancer	Monitors treatment response and recurrence

*Correspondence: Amisha Biswal, Department of Biotechnology, MITS School of Biotechnology, Bhubaneswar, Odisha, India. e-mail: biswalamisha316@gmail.com

© 2024 The Author(s). Published by Reseapro Journals. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Individualized cancer treatment and biomarkers

The conception of individualized cancer treatment involves acclimatizing treatment strategies grounded on the existent's inheritable and molecular profile, rather than a general, one-size-fits-all approach. Cancer biomarkers are central to the development of substantiated curatives, as they enable clinicians to elect medicines or interventions that target the specific molecular characteristics of a case's excrescence [5,10]. This approach, also known as perfection drug, aims to maximize remedial efficacy and minimize adverse goods by choosing the right treatment for the right case at the right time. Several exemplifications illustrate how cancer biomarkers are used in individualized drug targeted remedy. Targeted curatives are medicines designed to target specific inheritable mutations or molecular pathways driving cancer growth. For cases, the presence of BRAF mutations in carcinoma cases can guide the use of BRAF impediments, significantly perfecting patient issues. Also, HER2-positive bone cancer cases profit from trastuzumab (Herceptin), a monoclonal antibody that targets the HER2 receptor [11].

Immunotherapy Cancer immunotherapy, which harnesses the body's vulnerable system to fight cancer, also relies on biomarkers. The expression of PD-L1, a protein that inhibits vulnerable responses, can guide the use of vulnerable checkpoint impediments, similar as pembrolizumab, in cancers like lung cancer and carcinoma.

Liquid Biopsy Liquid vivisection, which involves assaying blood or other fleshly fluids for inheritable mutations and other biomarkers, is a non-invasive volition to traditional vivisection. Liquid necropsies can describe inheritable mutations similar as EGFR and ALK in lung cancer, allowing for individualized treatment opinions [12]. This approach also helps cover treatment response and descry minimum residual complaint.

Impact on case issues

Individual treatment, powered by cancer biomarkers, has shown promising results in perfecting case issues. crucial benefits include early Discovery and opinion Biomarkers allow for earlier discovery of cancer, occasionally indeed before clinical symptoms appear. Beforehand discovery significantly improves treatment issues, as excrescences are more treatable in their original stages. For case, the use of the CA-125 biomarker in ovarian cancer helps identify excrescences in asymptomatic cases, easing earlier intervention [12,13].

Acclimatized remedial Strategies By understanding the specific biomarkers associated with a case's excrescence, healthcare providers can customize treatment plans to increase efficacy [14]. For illustration, using targeted curatives grounded on inheritable mutations results in advanced response rates and smaller side goods compared to conventional chemotherapy.

Monitoring Treatment Response and Rush Cancer biomarkers also aid in covering how well a case is responding to treatment. A decline in biomarker situations may indicate treatment success, while an increase may gesture resistance or rush. Liquid vivisection offers a less invasive way to cover these changes in real-time.

Reduced toxin and Side goods Traditional treatments like chemotherapy affect both cancerous and healthy cells, leading to significant side goods [4,9]. With substantiated treatment, curatives can be chosen that specifically target the cancer, sparing normal towel and reducing adverse goods, therefore perfecting the case's quality of life.

Challenges and future directions

The identification of dependable and reproducible cancer biomarkers is a complex and time-consuming process. Numerous biomarkers still warrant sufficient clinical confirmation, and their perceptivity and particularity may vary across different populations.

Cost and Availability individualized cancer curatives can be precious, and access to advanced biomarker-grounded diagnostics is limited, particularly in low-resource settings. icking indifferent access to these life-saving technologies is essential [15].

Tumor Heterogeneity Cancer excrescences are frequently miscellaneous, meaning that they can parade different inheritable and molecular biographies within the same case [16,17]. This makes it delicate to identify a single biomarker or remedial target for every excrescence, taking ongoing monitoring and adaptation of treatment plans.

Ethical Considerations The use of inheritable and molecular data raises ethical issues, similar as sequestration enterprises, inheritable demarcation, and informed concurrence [17]. These issues must be addressed to ensure that cases are defended, and their rights are upheld.

Conclusion

Cancer biomarkers play a vital part in the period of individualized drug, offering promising avenues for earlier opinion, bettered treatment strategies, and better overall case issues. Through inheritable, proteomic, and epigenetic perceptivity, biomarkers enable clinicians to knitter curatives to the individual case, adding the liability of treatment success while minimizing gratuitous side goods. While challenges persist, the continued development of new biomarkers, coupled with advancements in technology and lesser availability, will probably transfigure cancer care in the times to come.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

1. Foroutan B. Personalized medicine: a review with regard to biomarkers. *J Bioequiv Availab*. 2015;7(6):244-256. <https://doi.org/10.4172/jbb.1000248>
2. Kamel HF, Al-Amodi HS. Exploitation of gene expression and cancer biomarkers in paving the path to era of personalized medicine. *Genom Proteom Bioinform*. 2017;15(4):220-235. <https://doi.org/10.1016/j.gpb.2016.11.005>
3. Jain KK. Role of biomarkers in personalized medicine. *Textbook of Personalized Medicine*. 2021:103-113. https://doi.org/10.1007/978-3-030-62080-6_3
4. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. *Eur Urol*. 2007;52(6):1601-1609. <https://doi.org/10.1016/j.eururo.2007.09.036>
5. Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in cancer detection, diagnosis, and prognosis. *Sensors*. 2023;24(1):37.

- <https://doi.org/10.3390/s24010037>
6. Schneider JE, Sidhu MK, Doucet C, Kiss N, Ohsfeldt RL, Chalfin D. Economics of cancer biomarkers. *Pers Med*. 2012;9(8):829-837. <https://doi.org/10.2217/pme.12.87>
 7. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, et al. Proteomic contributions to personalized cancer care. *Mol Cell Proteomics*. 2008;7(10):1780-1794. <https://doi.org/10.1074/mcp.R800002-MCP200>
 8. Msaouel P, Lee J, Karam JA, Thall PF. A causal framework for making individualized treatment decisions in oncology. *Cancers*. 2022;14(16):3923. <https://doi.org/10.3390/cancers14163923>
 9. Cheng T, Zhan X. Pattern recognition for predictive, preventive, and personalized medicine in cancer. *EPMA J*. 2017;8:51-60. <https://doi.org/10.1007/s13167-017-0083-9>
 10. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. *Transl Cancer Res*. 2015;4(3):256. <https://doi.org/10.3978/j.issn.2218-676X.2015.06.04>
 11. Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in colorectal cancer: current research and future prospects. *Int J Mol Sci*. 2020;21(15):5311. <https://doi.org/10.3390/ijms21155311>
 12. Leung F, Kulasingam V, Diamandis EP, Hoon DS, Kinzler K, Pantel K, et al. Circulating tumor DNA as a cancer biomarker: fact or fiction? *Clin Chem*. 2016;62(8):1054-1060. <https://doi.org/10.1373/clinchem.2016.260331>
 13. Saumet A, Lecellier CH. microRNAs and personalized medicine: Evaluating their potential as cancer biomarkers. *microRNA: medical evidence: from molecular biology to clinical practice*. 2015. 5-15p. https://doi.org/10.1007/978-3-319-22671-2_2
 14. Jacob M, Lopata AL, Dasouki M, Abdel Rahman AM. Metabolomics toward personalized medicine. *Mass Spectrom Rev*. 2019;38(3):221-238. <https://doi.org/10.1002/mas.21548>
 15. Majchrzak-Celińska A, Baer-Dubowska W. Pharmacopigenetics: an element of personalized therapy? *Expert Opin Drug Metab Toxicol*. 2017;13(4):387-398. <https://doi.org/10.1080/17425255.2017.1260546>
 16. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. *Nat Rev Clin Oncol*. 2012;9(9):542-548. <https://doi.org/10.1038/nrclinonc.2012.127>
 17. Pritzker KP. Colon cancer biomarkers: implications for personalized medicine. *J Pers Med*. 2020;10(4):167. <https://doi.org/10.3390/jpm10040167>